Versant Venture Capital VI, L.P. - Sep 11, 2024 Form 4 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Role
10%+ Owner
Signature
Versant Venture Capital VI, L.P. By: Versant Ventures VI GP, L.P. Its: General Partner By: Versant Ventures VI GP-GP, LLC Its: General Partner By: /s/ Max Eisenberg Its: Chief Operating Officer
Stock symbol
GLUE
Transactions as of
Sep 11, 2024
Transactions value $
-$3,404,791
Form type
4
Date filed
9/13/2024, 06:44 PM
Previous filing
Aug 30, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GLUE Common Stock Sale -$3.25M -542K -7.97% $6.00 6.26M Sep 11, 2024 Direct F1, F2
transaction GLUE Common Stock Sale -$96.3K -16K -0.26% $6.00 6.24M Sep 12, 2024 Direct F2, F3
transaction GLUE Common Stock Sale -$57.1K -9.27K -0.15% $6.16 6.23M Sep 13, 2024 Direct F2, F4
holding GLUE Common Stock 2.1M Sep 11, 2024 See Footnote F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.00 to $6.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
F2 Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Each of Versant VI GP-GP and Versant VI GP may be deemed to share voting, investment and dispositive power over the shares held by Versant VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
F3 The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.00 to $6.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
F4 The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.02 to $6.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
F5 Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. Each of Versant Vantage I GP-GP and Versant Vantage I GP may be deemed to share voting, investment and dispositive power over the shares held by Versant Vantage I and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.